Advances in antiarrhythmic drug treatment of atrial fibrillation: Where do we stand now?

Heart Rhythm

Volumn 1, Issue 2, 2004, Pages 244-246

  Camm, A John ^a   Savelieva, Irina ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 5 [1 (ALPHA ETHYLIMINO 3,4 DIMETHOXYBENZYL) 1,2,3,4 TETRAHYDRO 6 QUINOLINYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ABANOQUIL; ADENOSINE A1 RECEPTOR ANTAGONIST; ALMOKALANT; AMBASILIDE; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ARH 050642; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CARIPORIDE; DRONEDARONE; E 0474; ERSENTILIDE; HMR 1402; L 768673; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; N [3 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]AMINO]PROPYL] 4 NITROBENZAMIDE; PIBOSEROD; POTASSIUM CHANNEL BLOCKING AGENT; SEROTONIN 4 ANTAGONIST; SODIUM CHANNEL BLOCKING AGENT; TECADENOSON; TEDISAMIL; TERIKALANT; TRECETILIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIARRHYTHMIC ACTIVITY; CALCIUM CURRENT; CELL MEMBRANE CONDUCTANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW; SODIUM CURRENT;

EID: 3042857292     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2004.02.023     Document Type: Note

References (17)

1. Wyse D.G. Waldo A.L. DiMarco J.P. Domanski M.J. Rosenberg Y. Schron E.B. Kellen J.C. Greene H.L. Mickel M.C. Dalquist J.E. Corley S.D. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825-1833
2. Hohnloser S.H. Kuck K.H. Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356 2000 1789-1794
3. Van Gelder I.C. Hagens V.E. Bosker H.A. Kingma J.H. Kamp O. Kingma T. Said S.A. Darmanata J.I. Timmermans A.J. Tijssen J.G. Crijns H.J. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 2002 1834-1840
4. Pedersen O.D. Bagger H. Kober L. Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376-380
5. Madrid A.H. Bueno M.G. Rebollo J.M. Marin I. Pena G. Bernal E. Rodriguez A. Cano L. Cano J.M. Cabeza P. Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 2002 331-336
6. Goette A. Staack T. Rocken C. Amdt M. Geller J.C. Huth C. Ansorge S. Klein H.U. Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation J Am Coll Cardiol 35 2000 1669-1677
7. Go A.S. Hylek E.M. Phillips K.A. Chang Y. Henault L.E. Selby J.V. Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370-2375
8. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology Circulation 84 1991 1831-1851
9. Connolly S.J. Schnell D.J. Page R.L. Wilkinson W.E. Marcello S.R. Pritchett E.L. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation Am J Cardiol 88 2001 974-979
10. Singh S. Zoble R.G. Yellen L. Brodsky M.A. Feld G.K. Berk M. Billing C.B. Jr. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102 2000 2385-2390
11. Echt D.S. Liebson P.R. Mitchell L.B. Peters R.W. Obias-Manno D. Barker A.H. Arensberg D. Baker A. Friedman L. Greene H.L. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 1991 781-788
12. Waldo A.L. Camm A.J. deRuyter H. Friedman P.L. MacNeil D.J. Pauls J.F. Pitt B. Pratt C.M. Schwartz P.J. Veltri E.P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol Lancet 348 1996 7-12
13. Bode F. Sachs F. Franz M.R. Tarantula peptide inhibits atrial fibrillation Nature 409 2001 35-36
14. Muller A. Cottwald M. Tudyka T. et al. Increase in gap junction conductance by an antiarrhythmic peptide Eur J Pharmacol 327 1997 65-72
15. Rahme M.M. Cotter B. Leistad E. Wadhwa M.K. Mohabir R. Ford A.P.D.W. Eglen R.M. Feld G.K. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation Circulation 100 1999 2010-2017
16. Shinagawa K. Mitamura H. Ogawa S. Nattel S. Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling Cardiovasc Res 54 2002 438-446
17. Billman G.E. RSD-1235 Cardiome. Curr Opin Investig Drugs 4 2003 352-354